|
For more than 50 years, Dubois’ Lupus Erythematosus and Related Syndromes has been recognized internationally as the go-to clinical reference on lupus and other connective tissue diseases. From basic scientific principles to practical points of clinical management, the updated 9th Edition provides extensive, authoritative coverage of systemic lupus erythematosus (SLE) and its related diseases in a logical, clearly written, user-friendly manner.
It’s an ideal resource for rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on all aspects of SLE, connective tissue diseases, and the antiphospholipid syndromes.
Table of Contents
SECTION 1 What Is Lupus?
1 History of Lupus, 1
2 Definition and Classification of Lupus and Lupus-Related Disorders, 15
3 The Epidemiology of Lupus, 23
SECTION 2 Pathogenesis
4 Overview of Lupus Pathogenesis, 44
5 Genetics of Human SLE, 54
6 Epigenetics of Lupus, 69
7 The Environment and the Host, 86
8 The Innate Immune System in SLE, 93
9 B Cells and Generation of Antibodies, 101
10 T Cells, 116
11 Adaptive and Innate Immunoregulatory Cells, 125
12 Cytokines in Lupus, 137
13 Immunometabolism, 153
14 Animal Models in Lupus, 164
SECTION 3 Mechanisms of Tissue Injury
15 Abnormalities in Immune Complex Clearance and Apoptotic Cell Clearance, 216
16 The Role of Complement in SLE, 224
17 Apoptosis and Inflammatory Forms of Cell Death, 237
18 Tissue Damage in Lupus: Free Radicals and Fibrosis, 248
19 Pathogenesis of Fibrosis-The Lung as a Model, 261
20 Pathogenesis of Lupus Nephritis, 269
21 Pathogenesis of Accelerated Atherosclerosis and Vascular Injury in Systemic Lupus Erythematosus, 294
22 Pathogenesis of Cutaneous Lupus, 305
23 Pathogenesis of Neuropsychiatric Lupus, 317
24 Pathogenesis of Antiphospholipid Antibody Syndrome, 324
25 Pathogenesis of Sjögren’s, 338
SECTION 4 Autoantibodies
26 Structure and Derivation of Autoantibodies, 340
27 Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes, 355
28 Antibodies Against ENA (Sm, RNP, SSA, SSB), 366
29 Antibodies Against C1q, 372
30 Antilipoprotein and Antiendothelial Cell Antibodies, 375
31 Drug-Induced Lupus Erythematosus, 377
SECTION 5 Clinical Aspects of Lupus
Erythematosus
32 Overview and Clinical Presentation, 389
33 Skin Disease in Cutaneous Lupus Erythematosus, 395
34 The Musculoskeletal System and Bone Metabolism, 407
35 Lupus and the Cardiopulmonary System, 418
36 Lupus and the Nervous System: Clinical Aspects, Psychopathology, and Imaging, 434
37 Gastrointestinal and Hepatic Systems, 457
38 Hematologic and Lymphoid Abnormalities in SLE, 473
39 Neonatal Lupus: Pathogenesis and Clinical Approaches, 486
40 Pregnancy and Autoimmune Disease, Reproductive and Hormonal Issues, 499
41 Systemic Lupus Erythematosus in Childhood and Adolescence, 520
42 Clinical Aspects of Antiphospholipid Syndrome, 532
43 Lupus and Infections, 543
44 Ocular, Aural, and Oral Manifestations of Lupus, 556
45 Clinical Aspects of Sjögren’s, 566
SECTION 6 Assessment of Lupus
46 Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Clinical Laboratory Tests in Systemic Lupus Erythematosus, 579
47 Differential Diagnosis and Disease Associations, 598
48 Incomplete Lupus, Undifferentiated Connective Tissue Disease, and Mixed Connective Tissue Disease, 606
49 Clinical Markers, Metrics, Indices, and Clinical Trials, 614
50 Lupus Biomarkers, 631
SECTION 7 Management of Lupus
51 Principles of Therapy, Local Measures, and NSAIDs, 640
52 Antimalarial Medications, 650
53 Systemic Glucocorticoid Therapy for SLE, 661
54 Immunosuppressive Drug Therapy, 673
55 Complementary and Alternative Medications, Specialized and Niche Therapies, 689
56 Adjunctive Treatments and Preventive Measures, 702
57 Targeted Therapies in SLE, 710
58 Management of Cutaneous Lupus Erythematosus, 719
59 Epidemiology and Management of Lupus Nephritis, 727
60 Management of Sjögren’s, 745
SECTION 8 Outcomes
61 Socioeconomic and Disability Aspects, 759
62 Prognosis and Mortality of SLE, 770
|
